Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Sara Farshchi Zarabi"'
1
Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia
Autor: Neil MacLean, Shawn Brennan, Adam C. Smith, Rose Hurren, Allison Berger, Xiaoming Wang, Razq Hakem, Marcela Gronda, Mark D. Minden, Sara Farshchi Zarabi, Simon Kavanagh, Tary Traore, G. Wei Xu, Aaron D. Schimmer, Emil F. Pai, Samir H. Barghout, Ondrej Halgas, Michael Milhollen, Marc L. Hyer, Parasvi S. Patel, Danny V. Jeyaraju
Publikováno v: Leukemia. 33:37-51
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy for which new therapeutic approaches are required. One such potential therapeutic strategy is to target the ubiquitin-like modifier-activating enzyme 1 (UBA1), the initiating enzyme
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72230303f8aa4b6b6f446cbbbf8ed1b4
https://doi.org/10.1038/s41375-018-0167-0
Zobrazit plný text záznamu
2
Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity
Autor: Xudong Liao, Sara Farshchi Zarabi, Christopher P. Ford, Xiaoyan Sun, Xin Qi, Yuning Hong, Yu Luo, Aaron D. Schimmer, Xinwen Zhang, Di Hu
Publikováno v: Acta neuropathologica
Both α-Synuclein (αSyn) accumulation and mitochondrial dysfunction have been implicated in the pathology of Parkinson's disease (PD). Although studies suggest that αSyn and its missense mutant, A53T, preferentially accumulate in the mitochondria,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::931c3d8865e6e3b4a1b0fc8971133ad3
https://pubmed.ncbi.nlm.nih.gov/30877431
Zobrazit plný text záznamu
3
Remissions after Third Induction Chemotherapy for Primary Non-Responders with Acute Myeloid Leukemia (AML) Are Uncommon and Short-Lived
Autor: Anna Rydlewski, Karen Yee, Sara Farshchi Zarabi, Andre C. Schuh, Amr Rostom, Steven M. Chan, Mark D. Minden, Andrzej Lutynski, Hassan Sibai, Vikas Gupta, Dina Khalaf, Aaron D. Schimmer
Publikováno v: Blood. 128:2800-2800
The outcome of adult patients with AML who are primary non-responders to two courses of induction chemotherapy is poor. However, the utility of a 3rd induction for a select subgroup of these patients is uncertain. Here, we evaluated the rates of resp
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d44b35435995ea5864b4bf149640e15
https://doi.org/10.1182/blood.v128.22.2800.2800
Zobrazit plný text záznamu
4
Results of Salvage Autologous Stem Cell Transplantation (ASCT) for Relapsed Multiple Myeloma (MM) in the Era of Novel Agents: Outcome of Patients (Pts) Receiving Prior Bortezomib (BTZ)-Based Therapy
Autor: Suzanne Trudel, Rodger E. Tiedemann, Anca Prica, Vishal Kukreti, Esther Masih-Khan, Donna E. Reece, Christine Chen, Sara Farshchi Zarabi
Publikováno v: Blood. 128:5821-5821
Background: A second (salvage) ASCT has frequently been offered to MM patients with relapsed disease who experience benefit from the first procedure. We have previously reported that pts undergoing a salvage ASCT in the era of VAD or thalidomide (tha
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::157083fd9fb059dcfdeba37e8c95af86
https://doi.org/10.1182/blood.v128.22.5821.5821
Zobrazit plný text záznamu
6
Newly Diagnosed Myeloma (MM) Patients (Pts) with High-Risk (HR) Cytogenetics By FISH: Is There a Role for Tandem Autologous Stem Cell Transplantation (ASCT)?
Autor: Anca Prica, Esther Masih-Khan, Sara Farshchi-Zarabi, Sophia Farooki, Gurdeep Parmar, Suzanne Trudel, Rodger E. Tiedemann, Vishal Kukreti, C. Chen, Donna E. Reece
Publikováno v: Blood. 126:3176-3176
Background: Recent analyses have suggested that newly diagnosed multiple myeloma (MM) patients with the high-risk (HR) chromosomal abnormalities del 17p and t(4;14) detected by FISH may benefit from bortezomib (BTZ)-based induction therapy and tandem
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3cd45875ff4409330367f1e9f0633260
https://doi.org/10.1182/blood.v126.23.3176.3176
Zobrazit plný text záznamu
7
A retrospective analysis of upfront tandem autologous stem cell transplantation (ASCT) for high-risk (HR) myeloma (MM) patients (Pts)
Autor: Christine Chen, Gurdeep Parmar, Suzanne Trudel, Rodger E. Tiedemann, Vishal Kukreti, Donna E. Reece, Sara Farshchi Zarabi, Sophia Farooki, Esther Masih-Khan, Anca Prica
Publikováno v: Journal of Clinical Oncology. 33:e19532-e19532
e19532 Background: Previously, the median progression-free survival (PFS) and overall survival (OS) of MM pts with HR cytogenetics by FISH was ~9 mos and ~18 mos, respectively, after single ASCT (C...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e8d0567567a713fb5b17de6064a2d310
https://doi.org/10.1200/jco.2015.33.15_suppl.e19532
Zobrazit plný text záznamu
8
Conversion of the Seattle Angina Questionnaire into EQ-5D utilities for ischemic heart disease: a systematic review and catalog of the literature
Autor: William Witteman, Harindra C. Wijeysundera, Maria C. Bennell, Sara Farshchi-Zarabi
Publikováno v: ClinicoEconomics and Outcomes Research: CEOR
Harindra C Wijeysundera,1–4Sara Farshchi-Zarabi,1William Witteman,5Maria C Bennell1 1Schulich Heart Centre, Division of Cardiology, Sunnybrook Health Sciences Centre, 2Institute of Health Policy, Management and Evaluation, University of Toronto, 3I
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be8ec2cdf7185966be31c26967fa3ab7
https://doi.org/10.2147/ceor.s63187
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje